Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hydroxymethyl

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Hydroxymethyl. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-000534-20 Sponsor Protocol Number: THAM05 Start Date*: 2005-03-15
    Sponsor Name:Addenbrooke's Hospital NHS Foundation Trust
    Full Title: Influence of brain tissue pH regulation on cerebral oxygenation and metabolism in patients with severe traumatic brain injury.
    Medical condition: Severe traumatic brain injury
    Disease:
    Population Age: Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001314-41 Sponsor Protocol Number: 69501 Start Date*: 2019-05-06
    Sponsor Name:
    Full Title: Kinetics of ivacaftor at Switch Orkambi Symkevi study
    Medical condition: Cystic fibrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000604-14 Sponsor Protocol Number: SPP301CRD15 Start Date*: 2005-08-24
    Sponsor Name:Speedel Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal di...
    Medical condition: Diabetic Nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) SE (Prematurely Ended) SK (Completed) DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-003281-40 Sponsor Protocol Number: ASTX727-03 Start Date*: 2021-10-19
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
    Medical condition: Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) ES (Restarted) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002317-22 Sponsor Protocol Number: VALZ-Pilot Start Date*: 2016-11-29
    Sponsor Name:Geriatric Centre, Umeå University hospital
    Full Title: Feasibility and effects on markers in spinal fluid in persons with early Alzheimer's disease when treated with Valaciklovir - open Fas II pilot study (VALZ-Pilot)
    Medical condition: Alzheimer´s disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003329-89 Sponsor Protocol Number: AI467-003 Start Date*: 2012-04-03
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-...
    Medical condition: Human Immunodeficiency Virus type 1 (HIV-1) infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001277-25 Sponsor Protocol Number: ST1472-DM-03-004 Start Date*: 2004-09-27
    Sponsor Name:SIGMA-TAU
    Full Title: A Phase III, Multicentre, Double Blinded Study in Patients with Chronic Hepatitis C who are Non-responders to prior PEGinterferon alpha + Ribavirin Therapy Comparing Treatment with Thymosin alpha 1...
    Medical condition: Treatment of Patients with Chronic Hepatitis C who are Non-responders to a course with approved doses of PEGinterferon alpha + Ribavirin
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001628-72 Sponsor Protocol Number: P001317 Start Date*: 2017-07-18
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
    Medical condition: Primary central nervous system lymphoma (PCNSL) is an aggressive Non-Hodgkin Lymphoma (NHL) mostly of B-cell origin, which exclusively invades the central nervous system compartment. It accounts fo...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001181-10 Sponsor Protocol Number: P003077 Start Date*: 2023-04-13
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...
    Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000883-16 Sponsor Protocol Number: 200699 Start Date*: 2014-07-03
    Sponsor Name:GlaxoSmithKline Research & Devlopment Ltd
    Full Title: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component
    Medical condition: COPD Subjects with an Asthmatic Component
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    17.1 100000004855 10009028 Chronic obstructive asthma (with obstructive pulmonary disease) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005249-51 Sponsor Protocol Number: A7881013 Start Date*: 2010-05-19
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent UK
    Full Title: A PHASE 2B, PARALLEL, DOUBLE BLIND, DOUBLE DUMMY, ACTIVE COMPARATOR AND PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK QD ADMINISTRATION OF PF-00610355 CRC-74...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) EE (Completed) BG (Completed) PL (Completed) DE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-000529-19 Sponsor Protocol Number: 201211 Start Date*: 2014-05-22
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD
    Medical condition: Subjects with COPD
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000497-30 Sponsor Protocol Number: FIS-VED-2017-01 Start Date*: 2018-05-28
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antire...
    Medical condition: Adult patients infected with HIV and without previous antiretroviral treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000620-17 Sponsor Protocol Number: DRKS00005503 Start Date*: 2014-04-28
    Sponsor Name:Landeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart
    Full Title: High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial
    Medical condition: Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003973-24 Sponsor Protocol Number: ZEP117115 Start Date*: 2013-01-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Multicenter Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily with Tiotropium 18 mcg Once Daily over 24 Weeks in Subjects with Chronic Obstructive Pulmonar...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001997-16 Sponsor Protocol Number: VX15-770-124 Start Date*: Information not available in EudraCT
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, 2-Part, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Init...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001827-38 Sponsor Protocol Number: DB2116961 Start Date*: 2014-08-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic...
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) RO (Completed) HU (Completed) SK (Completed) PL (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022798-32 Sponsor Protocol Number: DEX-TRA 02 Start Date*: 2010-12-14
    Sponsor Name:Menarini Ricerche S.p.A.
    Full Title: DOUBLE-BLIND, RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE ANALGESIC EFFECT OF A SINGLE ORAL ADMINISTRATION OF FOUR DIFFERENT COMBINATION DOSES OF DKP.TRIS WITH T...
    Medical condition: Severe pain following impacted third mandibular molar tooth extraction
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) HU (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001409-15 Sponsor Protocol Number: 201012 Start Date*: 2016-01-07
    Sponsor Name:GlaxoSmithKlineResearch & Developemnt Ltd
    Full Title: Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD.
    Medical condition: Subjects with COPD.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003452-32 Sponsor Protocol Number: CD19-CAR_Lenti Start Date*: 2021-01-13
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma...
    Medical condition: relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Diffuse Large B Cell Lymphoma or Primary Mediastinal B Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 21:38:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA